Recently the important function of the hypoxic tumor microenvironment in driving tumor progression and in the development of therapy resistance has been acknowledged, and in the tumor stroma HIF-1α has a key role which has led increased focus in clinical research to discover new therapeutics inhibiting this protein or its targets [8, 13–15]. This evidence concerns the gene HIF1A and neoplasm.